HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

OBJECTIVES: The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Lillemoe, Tamera J., Rendi, Mara, Tsai, Michaela L., Knaack, Monica, Yarosh, Rina, Grimm, Erin, Susnik, Barbara, Krueger, Janet, Olet, Susan, Swenson, Karen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166502/
https://www.ncbi.nlm.nih.gov/pubmed/34123431
http://dx.doi.org/10.1155/2021/6684629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166502/
https://www.ncbi.nlm.nih.gov/pubmed/34123431
http://dx.doi.org/10.1155/2021/6684629

Ejemplares similares